Journal
CUREUS JOURNAL OF MEDICAL SCIENCE
Volume 15, Issue 9, Pages -Publisher
SPRINGERNATURE
DOI: 10.7759/cureus.44835
Keywords
prothrombin g20210a factor ii mutation; heterozygous factor v leiden mutation; deep vein thrombosis (dvt); acute pulmonary embolism; venous thromboembolism (vte)
Categories
Ask authors/readers for more resources
Venous thromboembolism (VTE) is a chronic illness with many associated risk factors. Anticoagulation therapy is crucial in managing VTE, and the duration of treatment depends on the patient's risk.
Venous thromboembolism (VTE) is a chronic illness that includes pulmonary embolism (PE) and deep vein thrombosis (DVT), and many risk factors are associated. Anticoagulation therapy remains the cornerstone of venous thromboembolism management, and the duration of anticoagulation depends on the risk of venous thromboembolism.We report a case of a female with a combined heterozygosity of factor V Leiden and G20210A prothrombin gene mutation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available